B7-33 10 mg
Educational recon guide for a 10 mg B7-33 (relaxin-mimetic) research vial and microgram-to-low-mg unit mapping. Research use only — no established human therapeutic dose.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Once daily subcutaneous in secondary educational tables (study designs vary)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
4 units
Volume
0.040 mL
Doses per vial
50
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 4 u
Fill one 30-unit U-100 syringe to about 4 units (0.040 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
There is no validated human clinical dose for research-market B7-33. Preclinical work uses model-specific mg/kg schedules. Secondary educational charts for research vials often discuss roughly ~200–800 mcg/day up into low-milligram daily SC amounts — treat as recon math only.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Days 1–14 (intro) | 200 mcg0.2 mg | 4 u | 0.04 mL200 mcg daily — lower educational SC example |
| Days 15–42 (standard educational) | 500 mcg0.5 mg | 10 u | 0.10 mL500 mcg daily — mid educational example |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Higher educational · 1 mg daily × 28 | 1 mg1,000 mcg | 20 u | 0.20 mL1 mg daily — upper end of many community mcg→mg tables |
| Higher educational · 2 mg daily × 14 | 2 mg2,000 mcg | 40 u | 0.40 mLLow-mg daily example — still not a safety-endorsed human protocol |
Supplies planner
Using the guide’s phase ladder (200 mcg → 500 mcg per injection (phase ladder)) over a 42-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
42-day course
B7-33 10 mg vials
2 vials
~16.8 mg mg total peptide over this 42-day course at 200 mcg → 500 mcg per injection (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
2 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 2 vials = 4.0 mL total. Buy as 2× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
42+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~88 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg B7-33 vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·B7-33 is a single-chain derivative of the H2 relaxin B-chain designed as an RXFP1-biased research tool in fibrosis and vascular models.
- ·Calculator doses are milligrams: 0.2 mg = 200 mcg.
- ·Preclinical mg/kg schedules are not naive human vial schedules.
- ·Research use only.
Research context & considerations
B7-33 was developed as a simplified relaxin-family peptide analogue with anti-fibrotic and vascular research interest while aiming for simpler chemistry than full H2 relaxin. Human therapeutic dosing is not established; research powders are not approved drugs.
- ·Cardiovascular / fluid-balance signaling is part of relaxin biology — high-caution experimental compound.
- ·Not FDA-approved for any indication via research-vial channels.
- ·Pregnancy and pediatric use are outside research-hobby scope.
Catalog match
B7-33
10mg x 10 vials · from $80